Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQB 3473

Next Previous
Drug Profile

TQB 3473

Alternative Names: TQB-3473

Latest Information Update: 01 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Idiopathic thrombocytopenic purpura
  • No development reported Haematological malignancies

Most Recent Events

  • 24 Jul 2025 Chia Tai Tianqing Pharmaceutical Group plans a phase II trial for Idiopathic thrombocytopenic purpura (Treatment experienced) in China (PO, Tablet) (NCT07083739)
  • 30 Apr 2025 Phase-III clinical trials in Idiopathic thrombocytopenic purpura (Treatment-experienced) in China (PO) (NCT06900920)
  • 24 Jan 2025 Chia Tai Tianqing Pharmaceutical Group plans a phase-III trial for Idiopathic thrombocytopenic purpura

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top